

# INTERNATIONAL JOURNAL OF ADVANCES IN CASE REPORTS



e - ISSN - 2349 - 8005

Journal homepage: www.mcmed.us/journal/ijacr

# HIV TYPE-1 PATIENT'S SERUM POSITIVE BLOOD STATUS WAS CHANGED INTO SERUM NEGATIVE THROUGH 3 COURSE (ONE COURSE FOR 10 DAYS) KALLUNK OXIDE IMMUNOTHERAPY TREATMENT

# Ramakrishnan Madhusoodanan\*

U.S. NIH trained Principal Investigator, Project Site Office HIRS, Karoor, Ambalapuzha, Alleppey- District, Kerala, India. Traditional Alternative Medicine Res Ctr, TAMRC-INDIA, Velumparambil House, Kakkazhom-PO, Alleppey-5, Kerala, India.

	Corresponding Author:- Ramakrishnan Madhusoodanan E-mail: tamrc_in_org@yahoo.co.in
Article Info	ABSTRACT
Received 15/07/2015	The T- cells (CD3+, CD4+, and CD8+) immune response to kallunk oxide [Immunotherapy]
Revised 27/07/2015	treatment could changed the HIV type-1 patient's serum positive blood status into HIV type-1 serum
Accepted 02/08/2015	negative. In July- 2015, the most amazing study results as four (4) adult patients were performed
1	through a phase III cost effective intervention clinical study "Traditional Complementary and
Kev words: T-Cells.	Alternative Medicine (CAM) in the Treatment of HIV/AIDS" project. This is the recent interim study
•	results (from external laboratories) on the treatment of immunotherapy from a resource limitation
	country, India. Clinical Trial Registration ID: NCT01349062.

## INTRODUCTION

The participants with the baseline CD4+ T-cells >450 cu/mm<sup>3</sup> of HIV type-1 infected patients were enrolled in to the study. The pertained study is currently recruiting HIV+ patients. The 4 cases study results were most relevant and confirmed that the HIV cure by Kallunk Oxide (Immunotherapy) treatment, a Siddha medicine, is possible. ELISA, 4th- generation and Card tests are carried out The case study was conducted at the project site office (HIRS), Karoor, Ambalapuzha, Alleppey- District, Kerala, India. Dr. Madhusoodanan, Ramakrishnan, the principal investigator (PI) was carried out this study.

Traditional Alternative Medicine Research, India an organization of Traditional Alternative Medicine Res Ctr [IPF Code;10001796] is overseeing this study with appropriate informed consents were obtained under the U.S. HHS approved Institutional Review Board {IRB} and it's Data and Safety Monitoring Board (DSMB). The organization has an international status as IORG0004200 listed by the U.S. Office of Human Research Protections (OHRP).

## METHOD

After the three months follow-up,[ the baseline to 12 weeks] the 2 out of 4 HIV+ patient's study results were achieved HIV seronegative blood Statuses and the other two patients are reaching to that milestone. All four (4) patients have a history of 5 years HIV+ background and the fourth female participant has HIV+ caused diabetes mellitus (type-II). The once daily dose regimen on 10 days treatment as the booster dose 5 mg Kallunk oxide + 1995 mg antidote (Piper Longum) was given to 4 patients. No ART (Anti Retroviral Treatment) was used. No short term adverse effect was encountered. Another Siddha medicine for diabetes was taken to control the female patient's complex blood sugar level (case report-4). The case report -2 had infected with Herpes (HSV) and HIV.

### RESULTS

The 4 cases study results was most relevant and confirmed that the HIV cure by Kallunk Oxide (Immunotherapy) treatment, a Siddha medicine, is 100 per cent possible.



# **Case Report-1**

U85195 KL 1990 PTC 005887. PAN No.: AABCM 6	Sree 449H	kandath Road (EAST), Phone : 0484 41120	Ravipuram, Ko 00, 2357044, 2	Dechi - 16 2358066
LABORATORY TEST F	REPO	RT		Reports online : www.medivision.in
TIENT'S NAME : Mr.		Pat. ID :		Sample Coll. : 16/05/2015 13:18
E : 32 Years / MALE		Reg. DATE : 1	6/05/2015	Sample Acc. : 16/05/2015 13:58
FERRED BY Dr :		IP/ OP No. :		Report Auth. : 16/05/2015 17:35
ent Name : NA				Report Status : FINAL
Depa	irtm	ent Of Haema	atology	
				And a second second
Packed Cell Volume	:	48	%	40 - 54
Red Blood Cells Count	:	5.3	Million	s/cumm3.5 - 5.5
Mean Corpuscular Volume	:	90	fL	80 - 92
Mean Corpuscular Haemoglobin	:	31	Pg	27 - 32
Mean Corpuscular Haemoglobulin Concentration	:	35	%	32 - 36
RDW	:	13.0	%	11.5 - 15.0
PDW	•	12.2	fL	9 - 14
MPV	:	10.0	fL	8 - 12
P-LCR	: *** E	24.5 END OF REPORT ***	%	15 - 35

KWA

Dr. Kazi Wajid Husain, MD LABORATORY DIRECTOR & PATHOLOGIST

ANJU MOHANDAS :25/05/2015 10:23:12AM

# 162021

)TE : - L= Low , H= High, The tests marked with \* are not accredited by NABL.

Page 2 of 3

H.O.: Medivision Scan & Diagnostic Research Centre Pvt.Ltd. Medivision House, Sreekandath Road (EAST), Ravipuram, Kochi - 16 Phone : 0484 4112000, 2357044, 2358066, Fax : 0484 4037327 Email : info@medivision.in www.medivision.in

.



Anuroop G.M.Sc. (Med. Microbiology) Microbiologist

Page 4 of 4

ANJU MOHANDAS: 25/05/2015 10:23:18AM

H.O.: Medivision Scan & Diagnostic Research Centre Pvt.Ltd. Medivision House, Sreekandath Road (EAST), Ravipuram, Kochi - 16 Phone : 0484 4112000, 2357044, 2358066, Fax : 0484 4037327 Email : info@medivision.in www.medivision.in

NOTE 6-20-206 H= High

				með	ivision
	Sreeka	ndath Road (EAST), Ra	vipuram, Kochi -	16 Diagn	
: U85195 KL 1990 PTC 005887. PAN No.: AABCM	V 6449H	Phone : 0484 4112000,	2357044, 23500		
LABORATORY TEST	<b>FREPOR</b>	Т		Reports onlir	e : www.medivision.in
ATIENT'S NAME : Mr.		Pat. ID :	Sa	mple Coll. : 1	6/05/2015 13:18
GE : 32 Years / MALE		Reg. DATE : 1	6/05/2015 Sa	ample Acc. :1	6/05/2015 13:39
EFERRED BY Dr :		IP/ OP No. :	Re	eport Auth. : 2	3/05/2015 11:42
ient Name : NA		Hosp. Name :		Re	port Status : FINA
Da	nartmo	nt Of Microbic	loav		
De	partitie		UNITS	DEEEDENC	ERANGE
PARAMETER	<u>UB</u>	SERVED VALUE	UNITS	<u>REI ERENC</u>	LINANOL
CD 45 Percentage	:	100.0			
CD 45	:	Positive			
Serum Anti HSV I & II IaM		Negative(0.24)	A.I.	< 0.9	: Negative
		Storage Alle Carlos		>0.9 - <1.1	: Equivocal
Technique used : ELISA				> 1.1	: Positive
Serum Anti HSV I & II IgG	:	Negative (0.32)	A.I.	< 0.9	: Negative
				0.9-1.1	: Positive
Technique used : ELISA					
			()	000 3450	
Absolute Lymphocyte Count	:	1496	/uL	990 - 3150	
CD4 percentage	:	31.9	%	31 - 59	
Absolute CD4 Count		478.00	Cells/uL	424 - 1509	)
				10 00	
CD 8 Percentage	: 1	H 40	%	12 - 38	

Anuroop G.M.Sc.(Med.Microbiology) Microbiologist

NOTE: 620231= High

Page 1 of 4

ANJU MOHANDAS: 25/05/2015 10:23:18AM

H.O.: Medivision Scan & Diagnostic Research Centre Pvt.Ltd. Medivision House, Sreekandath Road (EAST), Ravipuram, Kochi - 16 Phone : 0484 4112000, 2357044, 2358066, Fax : 0484 4037327 Email : info@medivision.in www.medivision.in

# Ramakrishnan Madhusoodanan. / International Journal Of Advances In Case Reports, 2015;2(16):1007-1029.

N: U85195 KL 1990 PTC 005887. PAN No.: AAE	3CM 6449H	Phone : 0484 411200	Ravipuram, Ko 00, 2357044, 2	16 1358066
LABORATORY TE	ST REPC	DRT		Reports online : www.medivision.in
ATIENT'S NAME : Mr.		Pat. ID :		Sample Coll. : 16/05/2015 13:18
GE : 32 Years / MALE		Reg. DATE : 10	5/05/2015	Sample Acc. : 16/05/2015 13:57
EFERRED BY Dr :		IP/ OP No. :		Report Auth. : 16/05/2015 16:14
lient Name : NA				Report Status : FINAL
· D	epartm	ent Of Biochei	mistry	
PARAMETER	0	BSERVED VALUE	UNITS	REFERENCE RANGE
Random Blood Glucose	:	89.00	mg/dl	70 - 140
Cholesterol	:	202.0	mg/dl	< 200 Desirable 200-239 Borderline high
erum / CHOD-POD / End point)				> 240 High
Bilirubin Total erum / DPD / End point)		0.9	mg/dl	0 - 1.0
Bilirubin Direct erum / DPD / End point)	:	0.2	mg/dL	0.0 - 0.2
	***	END OF REPORT ***		



Dr. Kazi Wajid Husain, MD LABORATORY DIRECTOR & PATHOLOGIST

ANJU MOHANDAS :25/05/2015 10:23:12AM

162022

NOTE : - L= Low , H= High, The tests marked with \* are not accredited by NABL.

Page 3 of 3

H.O.: Medivision Scan & Diagnostic Research Centre Pvt.Ltd. Medivision House, Sreekandath Road (EAST), Ravipuram, Kochi - 16 Phone : 0484 4112000, 2357044, 2358066, Fax : 0484 4037327 Email : info@medivision.in www.medivision.in

	Sreekandath Road (EAST), Ravipuram,	Kochi - 16 Diagnostic Services You Can Trust
IN: U85195 KL 1990 PTC 005887. PAN No.: AA	Phone : 0484 4112000, 2357044 BCM 6449H	, 2358066
LABORATORY TE	EST REPORT	Reports online : www.medivision.in
PATIENT'S NAME : Mr.	Pat. ID :	Sample Coll. : 16/05/2015 13:18
AGE : 32 Years / MALE	Reg. DATE : 16/05/20	15 Sample Acc. : 16/05/2015 13:39
EFERRED BY Dr :	IP/ OP No. :	Report Auth. : 16/05/2015 15:58
lient Name : NA	Hosp. Name :	Report Status : FINA
	Department Of Microbiology	
PARAMETER	OBSERVED VALUE	
Serum Anti HIV I & II	: Non Reactive(0.068)	< COV : Non Reactive >= COV : Reactive
Cut Off	0.007	
Cut Off	: 0.237	
Note HIV ELISA is a screening te test result should be confi with sera containing RF or Negative reactions can occu the immune system is non-re should be interpreted in th HIV DUO ULTA (Combined det	: 0.237 st for the detection of HIV I & rmed with Western Blot. False other auto-antibodies and from r in acute illness & sometimes active. To arrive at the final e context of other diagnostic p ection of HIV antibody & P24 ar	II antibodies in serum. The positive reactions can occur persons with hepatic disease. in the very late cases where diagnosis the test result procedures like P24 Assay, tigen by ELEA. PCB CCD4 cour
Note HIV ELISA is a screening te test result should be confi with sera containing RF or Negative reactions can occu the immune system is non-re should be interpreted in th HIV DUO Ultra (Combined det etc. and the total clinical Technique used : ELISA	: 0.237 st for the detection of HIV I & rmed with Western Blot. False other auto-antibodies and from r in acute illness & sometimes active. To arrive at the final e context of other diagnostic p ection of HIV antibody & P24 ar status of the patient.	II antibodies in serum. The positive reactions can occur persons with hepatic disease. in the very late cases where diagnosis the test result rocedures like P24 Assay, tigen by ELFA), PCR, CD4 cour
Note HIV ELISA is a screening te test result should be confi with sera containing RF or Negative reactions can occu the immune system is non-re should be interpreted in th HIV DUO Ultra (Combined det etc. and the total clinical Technique used : ELISA	: 0.237 st for the detection of HIV I & rmed with Western Blot. False other auto-antibodies and from r in acute illness & sometimes active. To arrive at the final e context of other diagnostic p ection of HIV antibody & P24 ar status of the patient. *** END OF REPORT ***	II antibodies in serum. The positive reactions can occur persons with hepatic disease, in the very late cases where diagnosis the test result procedures like P24 Assay, tigen by ELFA), PCR, CD4 cour
Note HIV ELISA is a screening te test result should be confi with sera containing RF or Negative reactions can occu the immune system is non-re should be interpreted in th HIV DUO Ultra (Combined det etc. and the total clinical Technique used : ELISA	: 0.237 st for the detection of HIV I & rmed with Western Blot. False other auto-antibodies and from r in acute illness & sometimes active. To arrive at the final e context of other diagnostic p ection of HIV antibody & P24 ar status of the patient. *** END OF REPORT ***	II antibodies in serum. The positive reactions can occur persons with hepatic disease. in the very late cases where diagnosis the test result procedures like P24 Assay, tigen by ELFA), PCR, CD4 cour
Note HIV ELISA is a screening te test result should be confi with sera containing RF or Negative reactions can occu the immune system is non-re should be interpreted in th HIV DUO Ultra (Combined det etc. and the total clinical Technique used : ELISA	: 0.237 st for the detection of HIV I & rmed with Western Blot. False other auto-antibodies and from r in acute illness & sometimes active. To arrive at the final e context of other diagnostic p ection of HIV antibody & P24 ar status of the patient. *** END OF REPORT ***	II antibodies in serum. The positive reactions can occur persons with hepatic disease. in the very late cases where diagnosis the test result rocedures like P24 Assay, tigen by ELFA), PCR, CD4 cour
Note HIV ELISA is a screening te test result should be confi with sera containing RF or Negative reactions can occu the immune system is non-re should be interpreted in th HIV DUO Ultra (Combined det etc. and the total clinical Technique used : ELISA	: 0.237 st for the detection of HIV I & rmed with Western Blot. False other auto-antibodies and from r in acute illness & sometimes active. To arrive at the final e context of other diagnostic p ection of HIV antibody & P24 ar status of the patient. *** END OF REPORT ***	II antibodies in serum. The positive reactions can occur persons with hepatic disease. in the very late cases where diagnosis the test result procedures like P24 Assay, tigen by ELFA), PCR, CD4 cour
Note HIV ELISA is a screening te test result should be confi with sera containing RF or Negative reactions can occu the immune system is non-re should be interpreted in th HIV DUO Ultra (Combined det etc. and the total clinical Technique used : ELISA	: 0.237 st for the detection of HIV I & rmed with Western Blot. False other auto-antibodies and from r in acute illness & sometimes active. To arrive at the final e context of other diagnostic p ection of HIV antibody & P24 ar status of the patient. *** END OF REPORT ***	II antibodies in serum. The positive reactions can occur persons with hepatic disease. in the very late cases where diagnosis the test result rocedures like P24 Assay, tigen by ELFA), PCR, CD4 cour
Note HIV ELISA is a screening te test result should be confi with sera containing RF or Negative reactions can occu the immune system is non-re should be interpreted in th HIV DUO Ultra (Combined det etc. and the total clinical Technique used : ELISA	: 0.237 st for the detection of HIV I & rmed with Western Blot. False other auto-antibodies and from r in acute illness & sometimes active. To arrive at the final e context of other diagnostic p ection of HIV antibody & P24 ar status of the patient. *** END OF REPORT ***	II antibodies in serum. The positive reactions can occur persons with hepatic disease. in the very late cases where diagnosis the test result procedures like P24 Assay, tigen by ELFA), PCR, CD4 cour
Note HIV ELISA is a screening te test result should be confi with sera containing RF or Negative reactions can occu the immune system is non-re should be interpreted in th HIV DUO Ultra (Combined det etc. and the total clinical Technique used : ELISA	<pre>st for the detection of HIV I &amp; rmed with Western Blot. False other auto-antibodies and from r in acute illness &amp; sometimes active. To arrive at the final e context of other diagnostic p ection of HIV antibody &amp; P24 ar status of the patient. *** END OF REPORT ***</pre>	II antibodies in serum. The positive reactions can occur persons with hepatic disease. in the very late cases where diagnosis the test result procedures like P24 Assay, tigen by ELFA), PCR, CD4 cour
Note HIV ELISA is a screening te test result should be confi with sera containing RF or Negative reactions can occu the immune system is non-re should be interpreted in th HIV DUO Ultra (Combined det etc. and the total clinical Technique used : ELISA	<pre>st for the detection of HIV I &amp; rmed with Western Blot. False other auto-antibodies and from r in acute illness &amp; sometimes active. To arrive at the final e context of other diagnostic p ection of HIV antibody &amp; P24 ar status of the patient. *** END OF REPORT ***</pre>	II antibodies in serum. The positive reactions can occur persons with hepatic disease. in the very late cases where diagnosis the test result procedures like P24 Assay, tigen by ELFA), PCR, CD4 cour
Note HIV ELISA is a screening te test result should be confi with sera containing RF or Negative reactions can occu the immune system is non-re should be interpreted in th HIV DUO Ultra (Combined det etc. and the total clinical Technique used : ELISA	<pre>st for the detection of HIV I &amp; rmed with Western Blot. False other auto-antibodies and from r in acute illness &amp; sometimes active. To arrive at the final e context of other diagnostic p ection of HIV antibody &amp; P24 ar status of the patient. *** END OF REPORT ***</pre>	II antibodies in serum. The positive reactions can occur persons with hepatic disease. in the very late cases where diagnosis the test result procedures like P24 Assay, tigen by ELFA), PCR, CD4 cour
Note HIV ELISA is a screening te test result should be confi with sera containing RF or Negative reactions can occu the immune system is non-re should be interpreted in th HIV DUO Ultra (Combined det etc. and the total clinical Technique used : ELISA	<pre>: 0.237 st for the detection of HIV I &amp; rmed with Western Blot. False other auto-antibodies and from r in acute illness &amp; sometimes active. To arrive at the final e context of other diagnostic p ection of HIV antibody &amp; P24 ar status of the patient. *** END OF REPORT ***</pre>	II antibodies in serum. The positive reactions can occur persons with hepatic diseases in the very late cases where diagnosis the test result procedures like P24 Assay, tigen by ELFA), PCR, CD4 cour
Note HIV ELISA is a screening te test result should be confi with sera containing RF or Negative reactions can occu the immune system is non-re should be interpreted in th HIV DUO Ultra (Combined det etc. and the total clinical Technique used : ELISA Notee2025, H= High	<pre>st for the detection of HIV I &amp; rmed with Western Blot. False other auto-antibodies and from r in acute illness &amp; sometimes active. To arrive at the final e context of other diagnostic p ection of HIV antibody &amp; P24 ar status of the patient. *** END OF REPORT *** Antibolity of the second se</pre>	II antibodies in serum. The positive reactions can occur persons with hepatic disease in the very late cases where diagnosis the test result procedures like P24 Assay, tigen by ELFA), PCR, CD4 cour
Note HIV ELISA is a screening te test result should be confi with sera containing RF or Negative reactions can occu the immune system is non-re should be interpreted in th HIV DUO Ultra (Combined det etc. and the total clinical Technique used : ELISA Not 162025 H= High	<pre>st for the detection of HIV I &amp; rmed with Western Blot. False other auto-antibodies and from r in acute illness &amp; sometimes active. To arrive at the final e context of other diagnostic p ection of HIV antibody &amp; P24 ar status of the patient. *** END OF REPORT *** Anti- Mice</pre>	II antibodies in serum. The positive reactions can occur persons with hepatic disease in the very late cases where diagnosis the test result procedures like P24 Assay, tigen by ELFA), PCR, CD4 cour Second Second Second Second Free Second Second Second Second Second robiologist

## Ramakrishnan Madhusoodanan. / International Journal Of Advances In Case Reports, 2015;2(16):1007-1029.

		<b>*</b> 2
Age: 33 Years	Sex:MALE	SID:
RÉPORT Tel No:		Collection DateTime 09/03/2015 11:39 Al Registration DateTime 09/03/201511:39 Al
Ref:Dr.		Report DateTime 16/03/2015 11:30 AM
Test Description Infections :	Observed Value	Biological Reference Interval with Units
HSV 1+2-IgG Antibodies, serum by ELISA	NON REACTIVE (0.25)	Non Reactive : 0 - 0.9 Equivocal : 0.91 - 1.1. Reactive : >1.1
HSV 1+2-IgM Ab, serum by ELISA	NON REACTIVE (0.32)	Non Reactive : 0 - 0.9 Equivocal : 0.91 - 1.1 Reactive : >1.1
	End of Report	



1013

REPORT	Age: 33 Years Sex:MALE Tel No:	PID NO: Collection DateTime: 09/03/2015 11:39 AM
		Registration DateTime: 09/03/201511:39 AM Report DateTime:
	Ref:Dr.	16/03/2015 11:30 AM
Test Description	Observed Value	<b>Biological Reference Interval with Units</b>

IMMUNOASSAY : HIV 1&2 by CMIA (IV th Generation test) Serum

NON REACTIVE (0.18)

<1.00 COI Non reactive >=1.00 COI Reactive

### Infections

RPR (VDRL) Test by Flocculation Serum

NON REACTIVE

Non reactive



-4	Age: 33 Years Sex:MAL	-		SID:
REPORT	Tel No:			Collection DateTime:
REFORT				09/03/2015 11:39 AM
				Registration DateTime
				09/03/201511:39 AM
	Ref:Dr.			Report DateTime:
		Haemogram		10/00/2010 11:50 AM
Test Description	0	bserved Value	Reference range	& Units
Erythrocytes:				
Erythrocyte Count, ED	TA blood, Automated	5.33	4.7 to 6.0 mill/c.mm	
Haemoglobin,EDTA blo	ood by AECI	16.8	13.5 to 18 gm/dL	
PCV (Packed Cel: Volu	me),EDTA Blood by AECI	48.1	12 to 52%	
MCV (Mean Corpuscula	ar Volume),EDTA Blood	90.0	78 to 100 fl.	
MCH (Mean Corpuscul	ar Haemoglobin),EDTA	31.5	27 to 31 pg	
MCHC (Mean Corpuscu	ular Haemoglobin	34.9	30 to 35%	
RDW (RedCell Distribu	tion Width), EDTAblood ,	12.3	11.5 to 14 %	
Leucocytes:				
Total Leucocytes, EDT.	A Blood by AECI	8,400	4,000 to 11,000/uL	
Neutrophils		64	40 to 80%	
Lymphocytes		34	20 to 40%	
Eosinophils		1	1 to 6%	
Monocytes		1	0 to 3 %	
Basophils			0 - 2 %	
* Differntial count is based	on 10,000 cells			
Platelets:				
Platelet count, EDTA Bl	ood, by AECI	2.52	1.5to 4.5 Lakhs/uL	
ESR-Erythrocyte Sedim	nentation	6	< ?0 mm/hour	



1015

Mr.	Reference: Sample Collected At:	VID: Registered On:
PID NO: Age: 33 Year(s) Sex: Male	ENDOCRINOLOGY & IMMUNOLOGY LAB North Square, Paramara Road, Opp.Town Ha Ernakulam, Cochin-682 018 <b>Zone: OUT-01(OS)682018</b>	10/03/2015 12:43 PM Collected On: 10/03/2015 Reported On: 11/03/2015 08:20 PM

### CD3/CD4/CD8 Test

Test Description	Observed Value	Unit	Biological Reference Interval
CD 45 absolute(Lymphocyte gated)	2566	/c.mm	1115-4009
CD 3 (T Cells) Percentage	71.46	%	55-81
CD 3 (T Cells) Absolute	1834	cells/µL	457-3926
CD 4 (Helper T Cells) Percentage	31.00	%	27-51
CD 4 (Helper T Cells) Absolute	795	cells/µL	448-1611
CD 8 (Suppressor T-Cells) Percentage	30.04	%	20.06-42.52
CD 8 (Suppressor T-Cells) Absolute	771	cells/µL	218-1396
CD 4/CD 8 ratio	1.03		0.39-3.02

Ramesh Kumar M.S.c., PhD Dr. Roshini Anand Patel MBBS, DCP Renjith K. Soorj M.S.c. Laboratory Director Consultant Pathologist Dept. of BOS employ

•

S, DCP Renjith K, Soorj M, Sc Dept. of Bogenemetry Kenny D, Jourg M, Sc Dept. of Bogenemetry Consultant Pathologi MD(Path), DNB, Offer Consultant Pathologist & Refer to conditions of reporting overleaf Head Acaboratory Services te only to the sample as received

El Lab Metropolis

INNER HEALTH REVEALED North Square, Paramara Road, Opp. Town Hall, Ernakulam North, Kochi-682 018 0484-4000123/124. Fax : 0484-400012

EI LAB Specialis



Technique : Flow Cytometry Single Platform Technology.

Specimens are sequentially gated as follows:

CD45 Leucocyte common antigen >> CD3 T-cells >> CD4 Helper T-cells >> CD8 Suppressor T-cells

#### Interpretation guidelines:

- CD4 counts may change upto 30% without any change in clinical status due to biological and method variation. Therefore, 1. trends over time should be monitored rathar than change in a specific test result. (Ref: J Wallach : Interpretation of laboratory medicine)
- For monitoring, both CD4% & Absolute CD4 counts should be considered. However, Absolute CD4 counts can show 2. variation as it is dependant absolute lymphocyte count (CD45) & total T-cell count (CD3) within a sample which in turn are affected by various infective/inflammatory conditions. While CD 4% is considered a stable parameter as it shows minimal biological variation & least dependent on absolute counts within a sample.
- An unexpected result must be repeated before changing therapy. 3.
- Very low CD4/8 absolute cell counts and percentages though satisfactorily acquired by the flow cytometer could be 4 associated with cellular degeneration, hence correlation with clinical findings & viral load is advised. If clinically indicated kindly repeat the test with fresh sample.
- Factors affecting CD4/CD8 counts: 5.

Circannual rhythm, Age, Sex, ethnic origin, stress, effect of drugs, presence of anti lympocyte antibody, spleenectomy, menstrual cycle, smoking, infections, pregnancy,

- Time of collection, delay in analysis, sequential use of different assay and sample storage. \*\* CD8 counts are not enumerated if request is made for CD4 counts only.

#### **Reference** :

\* Thakar et al. Establishment of reference CD4+ T cell values for adult Indian population. AIDS Research and Therapy 2011, 8:35 \* Uppal et al. Normal Values of CD4 and CD8 Lymphocyte Subsets in Healthy Indian Adults and the Effects of Sex, Age, Ethnicity, and Smoking. Cytometry Part B (Clinical Cytometry) 52B:32-36 (2003)

Giorgi JV, Hultin LE, Lymphocyte subset alterations and immunophenotyping by flow cytometry in HIV disease. Clin Immunol Newslett. 1990;10:55-61.

Landay A, Ohlsson-William B, Giorgi JV. Application of flow cytometry to the study of HIV infection. AIDS. 1990; 4:479-497. Centers for Disease Control. 1997 Revised guidelines for performing CD4+ T-cell determinations in persons with human immunodeficiency virus (HIV). MMWR.1997;46 (No.RR-2), 1-29.

-- End of Report --

Dr. Ramesh Kumar M.Sc., PhD Dr. Roshini Anand Patel MBBS, DCP Renjith K. Soori M.S I abaratary Director Consultant Pathologist Dept **Page** Renkey Kenny D'Souza M.Sc. D. Nisha M.Sc. Dr. Siva Mathur Bansal MBBS MD Dept of Raiesh Bendler, of Serology Consultant Pathologi MD(Path), DNB, DPBromiefer athologist & Laboratory Director Refer to conditions of reporting overleaf Head Paboratory Services late only FLAB El Lab Metropolis INNER HEALTH REVEALED North Square, Paramara Road, Opp. Town Hall, Ernakulam North, Kochi-682 018 0484-4000123/124, Fax: 0484-4000126 The Pathology Specialist

	LAB DEPORT	,
Patient : MR.	(32 Yrs., Male)	
Address :		Sample Date : 24/06/2015
Doctor :.		
Bill No :		Result Date : 24/06/2015
Name of Tant	DEPARTMENT OF BIOCHEMIS	TRY
Name of Test	Result	Normal Value
QH 1615		
		•

N



SNOSTIC REPORT					
		•		· · ·	ÈSKL
		ann	8	#2.	Diagnostics
1000111 Her 2017	CAD BODY ROOM WATCHED TH	ACCREDITE	2 m		
CLIENT CODE :		SRL LIMITED			
CLIENT'S NAME AND ADDRESS : DDRC SRL DIAGNOSTICS (PVT.) LTD. KOTTAYAM OTHALATHUMOOTTIL BUILDING, SAMKRANTHY JUNC	TION,	PRIME SQUAR ESTATE, S.V. I MUMBAI, 400	RE BUILDING,PL ROAD,GOREGAC 062	OT NO 1,GAIWADI IN DN (W)	DUSTRIAL
KOTTAYAM 686028 KERALA INDIA 481-2595573		MAHARASHTF Tel: 022-678 CIN - U74899 Email: srl.mu	RA, INDIA 01177, 1800-22 DL1995PLC0700 Imbai@srl.in	22-660, Fax : 022 - 67 603	7801212
PATIENT NAME : MR.		÷	PA	TIENT ID :	
ACCESSION NO : AGE :	39 Years SEX : Male	e DA	TE OF BIRTH :		
DRAWN : 13/01/2015 17:00 RECEIV	/ED: 15/01/2015 01:2	.9	REPORTED :	15/01/2015 16:26	5
		in the second second	CLIENT	PATIENT ID :	
	Posults		Biological R	eference Interva	Units
Test Report Status <u>Final</u>	Kesuits		Diological is		
					1
	FLOW CYTOMET	RY			j
LYMPHOCYTE SUBSET ENUMERATION, BL	OOD				
% CD3+/CD45+ (T-CELLS)	74.7		59 - 84		%
ABSOLUTE CD3+ LYMPHOCYTE COUNT	2082		716 - 2130		/µL
% CD3+/CD4+ (T-HELPER CELLS)	34.5		26 - 48	-	%
ABSOLUTE CD4+ LYMPHOCYTE COUNT	963		354 - 1100		/µL
% CD3+/CD8+ (T-SUPPRESSOR CELLS)	37.0		18 - 41		%
	1032	High	192 - 980		/µL
	0.93		0.57 - 2.03		
CD4/CD8 RATIO	0.95		0.07 2.00		
Test Method(s) LYMPHOCYTE SUBSET ENUMERATION, BLOOD- LYMPHOCYTE SUBSET ENUMERATION Introduction: The lymphocyte population of human peripheral blood is com	posed of two cell types: T (thym	nus) derived and	B (bone marrow-o	derived). These cell types	are morphologically
Test Method(s) LYMPHOCYTE SUBSET ENUMERATION, BLOOD- LYMPHOCYTE SUBSET ENUMERATION Introduction: The lymphocyte population of human peripheral blood is com indistinguishable but can be identified by characteristic antige identify and enumerate peripheral blood mature helper/induc Applications: CD3, CD4 and/or CD8 positive lymphocyte percentages and a monitor lymphocyte levels following organ transplantation. D immunodeficiency diseases. For example, infection with hum- depletion of the CD4 positive lymphocytes that express the rr CD4 positive lymphocyte count. CD4/CD8 ratio is useful as di patients, with no detectable levels of CD4 lymphocytes. In su	posed of two cell types: T (thym nic profile on their cell membra er and supressor/cytotoxic.F c besolute counts are used as tool termination of levels of CD4 pc an immunodeficiency virus (HIV ceptor for the virus (the CD4 a agnostic and /or prognostic Indi ch cases, CO8 lymphocyte level	nus) derived and ine. The present ells via specific b sitive lymphocy ) results in prog ntigen). Clinical icators of immun s might be norm	B (bone marrow- test utilizes mono inding to cell surfa mune status, unde tes might also assi ressive immunosuj and immunologic c e competence. CD al, increased or de	lerived). These cell types clonal antibodies against of cc antigens, CD3, CD4 ar rlying known or unknown st in the diagnosis and /o oppression due predominar leterioration generally cor 4/CDB ratio falls toward z creased.	are morphologically CD3, CD4 and CD8 to ad CD8 respectively. disease states and to r monitoring of tity to a selective relates with a falling ero in advanced AIDS
Test Method(s) LYMPHOCYTE SUBSET ENUMERATION, BLOOD- LYMPHOCYTE SUBSET ENUMERATION Introduction: The lymphocyte population of human peripheral blood is com indistinguishable but can be identified by characteristic antige identify and enumerate peripheral blood mature helper/induc Applications: CD3, CD4 and/or CD8 positive lymphocyte percentages and a monitor lymphocyte levels following organ transplantation. D immunodeficiency diseases. For example, infection with huma depletion of the CD4 positive lymphocytes that express the re CD4 positive lymphocyte count. CD4/CD8 ratio is useful as di patients, with no detectable levels of CD4 lymphocytes. In su Technique: Absolute CD4 and CD8 counts are carried out using single pla analysis alone and is more accurate, compared to the "dual p	posed of two cell types: T (thym nic profile on their cell membra er and supresssor/cytotoxic.T co bsolute counts are used as tool termination of levels of CD4 pc an immunodeficiency virus (the ceptor for the virus (the CD4 a agnostic and /or prognostic indi ch cases, CD8 lymphocyte level tform (SP) technology. This tec latform" technology especially a	nus) derived and ine. The present ells via specific b is to evaluate im stitive lymphocy ) results in prog ntigen). Clinical. icators of immun ls might be norm chnology allows d at lower counts.	B (bone marrow- test utilizes mono- inding to cell surfa mune status, unde tes might also assi ressive immunosuj and immunologic c e competence. CD al, increased or de lirect measuremen	derived). These cell types clonal antibodies against of ce antigens, CD3, CD4 ar rlying known or unknown st in the diagnosis and /o pression due predominar leterioration generally cor 4/CD8 ratio falls toward z creased. t of lymphocyte subsets t	are morphologically CD3, CD4 and CD8 to d CD8 respectively. disease states and to r monitoring of tity to a selective relates with a falling ero in advanced AIDS
Test Method(s) LYMPHOCYTE SUBSET ENUMERATION, BLOOD- LYMPHOCYTE SUBSET ENUMERATION Introduction: The lymphocyte population of human peripheral blood is com indistinguishable but can be identified by characteristic antige identify and enumerate peripheral blood mature helper/induc Applications: CD3, CD4 and/or CD8 positive lymphocyte percentages and a monitor lymphocyte levels following organ transplantation. D immunodeficiency diseases. For example, infection with hum depletion of the CD4 positive lymphocytes that express the rf CD4 positive lymphocyte count. CD4/CD8 ratio is useful as di patients, with no detectable levels of CD4 lymphocytes. In su Technique: Absolute CD4 and CD8 counts are carried out using single pla analysis alone and is more accurate, compared to the "dual p GENDERWISE REFERENCE RANGES QUOTED ABOVE WERE G	posed of two cell types: T (thym nic profile on their cell membra er and supresssor/cytotoxic.T c bsolute counts are used as tool etermination of levels of CD4 pc an immunodeficiency virus (HIV ceeptor for the virus (the CD4 agnostic and /or prognostic indi ch cases, CD8 lymphocyte level tform (SP) technology. This tec latform* technology especially a ENERATED INHOUSE BY SINGLI	nus) derived and ine. The present ells via specific b sto evaluate im spitive lymphocy () results in prog ntigen). Clinical i cators of immun is might be norm chnology allows of at lower counts. E PLATFORM TEC	B (bone marrow-d test utilizes mono- inding to cell surfa mune status, unde tes might also assi ressive immunosuj and immunologic c e competence. CD al, increased or de lirect measuremen CHNOLOGY.	derived). These cell types clonal antibodies against ( cc antigens, CD3, CD4 ar rlying known or unknown st in the diagnosis and /o opression due predominar leterioration generally cor A/CDB ratio falls toward z creased. t of lymphocyte subsets t	are morphologically CD3, CD4 and CD8 to d CD8 respectively. disease states and to r monitoring of ntly to a selective relates with a falling ero in advanced AIDS by Flow Cytometric
Test Method(s) LYMPHOCYTE SUBSET ENUMERATION, BLOOD- LYMPHOCYTE SUBSET ENUMERATION Introduction: The lymphocyte population of human peripheral blood is com indistinguishable but can be identified by characteristic antige identity and enumerate peripheral blood mature helper/induc Applications: CD3, CD4 and/or CD8 positive lymphocyte percentages and a monitor lymphocyte levels following organ transplantation. D immunodeficiency diseases. For example, infection with hum- depletion of the CD4 positive lymphocytes that express the rr CD4 positive lymphocyte count. CD4/CD8 ratio is useful as di patients, with no detectable levels of CD4 lymphocytes. In su Technique: Absolute CD4 and CD8 counts are carried out using single pla analysis alone and is more accurate, compared to the "dual p GENDERWISE REFERENCE RANGES QUOTED ABOVE WERE G Methodology: Single Platform/Direct analysis using four-color reagent (CD4	posed of two cell types: T (thym nic profile on their cell membra er and supressor/cytotoxic.F c bsolute counts are used as tool termination of levels of CD4 pc an immunodeficiency virus (HIV ceptor for the virus (the CD4 a agnostic and /or prognostic Indi ch cases, CD8 lymphocyte level tform (SP) technology. This tec latform" technology especially a ENERATED INHOUSE BY SINGLI 5/CD3/CD4/CD8) with Flow Cot **End Of Report yorld.com for related Ter	nus) derived and ine. The present ells via specific b sitive lymphocy ) results in prog ntigen). Clinical icators of immun Is might be norm chnology allows d at lower counts. E PLATFORM TEC unt Flurospheres t**	B (bone marrow- test utilizes mono- inding to cell surfa- mune status, unde tes might also assi and immunologic c ecompetence. CD ial, increased or de lirect measuremen CHNOLOGY. for absolute count on for this acce	derived). These cell types clonal antibodies against of ce antigens, CD3, CD4 ar rlying known or unknown st in the diagnosis and /o pression due predominar leterioration generally cor 4/CD8 ratio falls toward z creased. t of lymphocyte subsets to t determination.	are morphologically CD3, CD4 and CD8 to dd CD8 respectively. disease states and to r monitoring of titly to a selective relates with a falling ero in advanced AIDS by Flow Cytometric
Test Method(s) LYMPHOCYTE SUBSET ENUMERATION, BLOOD- LYMPHOCYTE SUBSET ENUMERATION Introduction: The lymphocyte population of human peripheral blood is com indistinguishable but can be identified by characteristic antige identity and enumerate peripheral blood mature helper/induc Applications: CD3, CD4 and/or CD8 positive lymphocyte percentages and a monitor lymphocyte levels following organ transplantation. D immunodeficiency diseases. For example, infection with hum- depletion of the CD4 positive lymphocytes that express the rr CD4 positive lymphocyte count. CD4/CD8 ratio is useful as di patients, with no detectable levels of CD4 lymphocytes. In su Technique: Absolute CD4 and CD8 counts are carried out using single pla analysis alone and is more accurate, compared to the "dual p GENDERWISE REFERENCE RANGES QUOTED ABOVE WERE G Methodology: Single Platform/Direct analysis using four-color reagent (CD4	posed of two cell types: T (thym nic profile on their cell membra er and supressor/cytotoxic.F co bsolute counts are used as tool termination of levels of CD4 pc an immunodeficiency virus (HIV ceptor for the virus (the CD4 a agnostic and /or prognostic Indi ch cases, CD8 lymphocyte level tform (SP) technology. This tec latform" technology especially a ENERATED INHOUSE BY SINGLI 5/CD3/CD4/CD8) with Flow Cot **End Of Report yorld.com for related Te:	nus) derived and ine. The present ells via specific b sitive lymphocy ) results in prog ntigen). Clinical icators of immun Is might be norm chnology allows d at lower counts. E PLATFORM TEC unt Flurospheres t** st Informatic	B (bone marrow- test utilizes mono- inding to cell surfa- mune status, unde tes might also assi and immunologic c ecompetence. CD nal, increased or de lirect measuremen CHNOLOGY. for absolute count on for this acce	derived). These cell types clonal antibodies against ( cc antigens, CD3, CD4 ar rlying known or unknown st in the diagnosis and /o pression due predominar leterioration generally cor 4/CD8 ratio falls toward z ccreased. t of lymphocyte subsets to t determination.	are morphologically CD3, CD4 and CD8 to d CD8 respectively. disease states and to r monitoring of titly to a selective relates with a falling ero in advanced AIDS by Flow Cytometric
Test Method(s) LYMPHOCYTE SUBSET ENUMERATION, BLOOD- LYMPHOCYTE SUBSET ENUMERATION Introduction: The lymphocyte population of human peripheral blood is com indistinguishable but can be identified by characteristic antige identity and enumerate peripheral blood mature helper/induc Applications: CD3, CD4 and/or CDB positive lymphocyte percentages and a monitor lymphocyte levels following organ transplantation. D immunodeficiency diseases. For example, infection with hum depletion of the CD4 positive lymphocytes that express the rr CD4 positive lymphocyte count. CD4/CD8 ratio is useful as di patients, with no detectable levels of CD4 lymphocytes. In su Technique: Application e and is more accurate, compared to the "dual p GENDERWISE REFERENCE RANGES QUOTED ABOVE WERE G Methodology: Single Platform/Direct analysis using four-color reagent (CD4 Please visit www.srlv	posed of two cell types: T (thym nic profile on their cell membra er and supressor/cytoxic.F co bsolute counts are used as tool termination of levels of CD4 pc an immunodeficiency virus (HIV ceptor for the virus (the CD4 a agnostic and /or prognostic Indi ch cases, CD8 lymphocyte level tform (SP) technology. This tec latform" technology especially a ENERATED INHOUSE BY SINGLI 5/CD3/CD4/CD8) with Flow Cot **End Of Report vorld.com for related Te:	nus) derived and ine. The present ells via specific b sitive lymphocy ) results in prog ntigen). Clinical icators of immun Is might be norm chnology allows d at lower counts. E PLATFORM TEC unt Flurospheres t** st Informatic	B (bone marrow- test utilizes mono- inding to cell surfa tes might also assi ressive immunosuj and immunologic c e competence. CD tal, increased or de lirect measuremen CHNOLOGY. for absolute count on for this acce	derived). These cell types clonal antibodies against ( cc antigens, CD3, CD4 ar rlying known or unknown st in the diagnosis and /o pression due predominar leterioration generally cor 4/CDB ratio falls toward z ccreased. t of lymphocyte subsets t t determination. cssion	are morphologically CD3, CD4 and CD8 to d CD8 respectively. disease states and to r monitoring of titly to a selective relates with a falling ero in advanced AIDS by Flow Cytometric
Test Method(s) LYMPHOCYTE SUBSET ENUMERATION, BLOOD- LYMPHOCYTE SUBSET ENUMERATION Introduction: The lymphocyte population of human peripheral blood is com indistinguishable but can be identified by characteristic antige identify and enumerate peripheral blood mature helper/induce Applications: CD3, CD4 and/or CD8 positive lymphocyte percentages and a monitor lymphocyte levels following organ transplantation. D immunodeficiency diseases. For example, infection with huma depletion of the CD4 positive lymphocytes that express the rd CD4 positive lymphocyte count. CD4/CD8 ratio is useful as di patients, with no detectable levels of CD4 lymphocytes. In su Technique: Absolute CD4 and CD8 counts are carried out using single pla analysis alone and is more accurate, compared to the "dual p GENDERWISE REFERENCE RANGES QUOTED ABOVE WERE G Methodology: Single Platform/Direct analysis using four-color reagent (CD4 Please visit www.srlv Mathian State	posed of two cell types: T (thym nic profile on their cell membra er and supresssor/cytotoxic.T ci bsolute counts are used as tool an immunodeficiency virus (HIV sceptor for the virus (the CD4 a agnostic and /or prognostic indi ch cases, CD8 lymphocyte level tform (SP) technology especially a ENERATED INHOUSE BY SINGLI 5/CD3/CD4/CD8) with Flow Cou **End Of Report vorld.com for related Tes	nus) derived and ine. The present ells via specific b is to evaluate im spitive lymphocy () results in prog ntigen). Clinical i icators of immun is might be norm chnology allows d at lower counts. E PLATFORM TEC unt Flurospheres t**	B (bone marrow- test utilizes mono- inding to cell surfa eta singht also assi ressive immunosuj and immunologic c e competence. CD ial, increased or de lirect measuremen CHNOLOGY. for absolute count on for this acce	derived). These cell types clonal antibodies against ( cc antigens, CD3, CD4 ar rlying known or unknown st in the diagnosis and /o ppression due predominar leterioration generally cor 4/CDB ratio falls toward z creased. t of lymphocyte subsets t t determination. ession	are morphologically CD3, CD4 and CD8 to d CD8 respectively. disease states and to r monitoring of titly to a selective relates with a falling rero in advanced AIDS by Flow Cytometric
Test Method(s) LYMPHOCYTE SUBSET ENUMERATION, BLOOD- LYMPHOCYTE SUBSET ENUMERATION Introduction: The lymphocyte population of human peripheral blood is com indistinguishable but can be identified by characteristic antige identity and enumerate peripheral blood mature helper/induc Applications: CD3, CD4 and/or CD8 positive lymphocyte percentages and a monitor lymphocyte levels following organ transplantation. D immunodeficiency diseases. For example, infection with hum- depletion of the CD4 positive lymphocytes that express the rr CD4 positive lymphocyte count. CD4/CD8 ratio is useful as di patients, with no detectable levels of CD4 lymphocytes. In su Technique: Bosolute CD4 and CD8 counts are carried out using single pla analysis alone and is more accurate, compared to the "dual p GENDERWISE REFERENCE RANGES QUOTED ABOVE WERE G Methodology: Single Platform/Direct analysis using four-color reagent (CD4 Please visit www.srlv Dr. Vishal Mehrotra, MD Haematopathologist	posed of two cell types: T (thym nic profile on their cell membra er and supresssor/cytotoxic.T ci bsolute counts are used as tool etermination of levels of CD4 pc an immunodeficiency virus (HIV sceptor for the virus (the CD4 a agnostic and /or prognostic indi ch cases, CD8 lymphocyte level tform (SP) technology especially a ENERATED INHOUSE BY SINGLI S/CD3/CD4/CD8) with Flow Cou **End Of Report vorld.com for related Tes	nus) derived and ine. The present ells via specific b sitive lymphocy ) results in prog ntigen). Clinical icators of immun Is might be norm chnology allows d at lower counts. E PLATFORM TEC unt Flurospheres t** st Informatic	B (bone marrow- test utilizes mono- inding to cell surfa mune status, unde tess might also assi ressive immunosuj and immunologic c competence. CD ial, increased or de lirect measuremen CHNOLOGY. for absolute count on for this acco	derived). These cell types clonal antibodies against ( cc antigens, CD3, CD4 ar rlying known or unknown st in the diagnosis and /o ppression due predominar leterioration generally cor 4/CDB ratio falls toward z creased. t of lymphocyte subsets t t determination. ession	are morphologically CD3, CD4 and CD8 to d CD8 respectively. disease states and to r monitoring of titly to a selective relates with a falling ero in advanced AIDS by Flow Cytometric
Test Method(s) LYMPHOCYTE SUBSET ENUMERATION, BLOOD- LYMPHOCYTE SUBSET ENUMERATION Introduction: The lymphocyte population of human peripheral blood is com indistinguishable but can be identified by characteristic antige identity and enumerate peripheral blood mature helper/induc Applications: CD3, CD4 and/or CD8 positive lymphocyte percentages and a monitor lymphocyte levels following organ transplantation. D immunodeficiency diseases. For example, infection with hum- depletion of the CD4 positive lymphocytes that express the rr CD4 positive lymphocyte count. CD4/CD8 ratio is useful as di patients, with no detectable levels of CD4 lymphocytes. In su Technique: Bosolute CD4 and CD8 counts are carried out using single pla analysis alone and is more accurate, compared to the "dual po GENDERWISE REFERENCE RANGES QUOTED ABOVE WERE G Methodology: Single Platform/Direct analysis using four-color reagent (CD4 Please visit www.srlv Dr. Vishal Mehrotra, MD Haematopathologist	posed of two cell types: T (thym nic profile on their cell membra er and supresssor/cytotoxic.T ci boolute counts are used as tool an immunodeficiency virus (HIV ceeptor for the virus (the CD4 a agnostic and /or prognostic indi ch cases, CD8 lymphocyte level tform (SP) technology especially a ENERATED INHOUSE BY SINGLI 5/CD3/CD4/CD8) with Flow Cou **End Of Report vorld.com for related Tes	nus) derived and ine. The present ells via specific b sitive lymphocy ) results in prog ntigen). Clinical icators of immun Is might be norm chnology allows d at lower counts. E PLATFORM TEC unt Flurospheres t** st Informatic	B (bone marrow-d test utilizes mono- inding to cell surfa mune status, unde tess might also assi ressive immunosuj and immunologic c e competence. CD hal, increased or de lirect measuremen CHNOLOGY. for absolute count on for this acco	derived). These cell types clonal antibodies against ( icc antigens, CD3, CD4 ar rlying known or unknown sti in the diagnosis and /o ppression due predominar leterioration generally cor d/CDB ratio falls toward z creased. t of lymphocyte subsets to t determination.	are morphologically CD3, CD4 and CD8 to d CD8 respectively. disease states and to r monitoring of titly to a selective relates with a falling ero in advanced AIDS by Flow Cytometric
Test Method(s) LYMPHOCYTE SUBSET ENUMERATION, BLOOD- LYMPHOCYTE SUBSET ENUMERATION Introduction: The lymphocyte population of human peripheral blood is com indistinguishable but can be identified by characteristic antige identity and enumerate peripheral blood mature helper/induc Applications: CD3, CD4 and/or CD8 positive lymphocyte percentages and a monitor lymphocyte levels following organ transplantation. D immunodeficiency diseases. For example, infection with hum- depletion of the CD4 positive lymphocytes that express the rr CD4 positive lymphocyte count. CD4/CD8 ratio is useful as di patients, with no detectable levels of CD4 lymphocytes. In su Technique: Bosolute CD4 and CD8 counts are carried out using single pla analysis alone and is more accurate, compared to the "dual po GENDERWISE REFERENCE RANGES QUOTED ABOVE WERE G Methodology: Single Platform/Direct analysis using four-color reagent (CD4 Please visit www.srlv Dr. Vishal Mehrotra, MD Haematopathologist	posed of two cell types: T (thym nic profile on their cell membra er and supresssor/cytotoxic.T ci boolute counts are used as tool etermination of levels of CDA pc an immunodeficiency virus (HIV ceeptor for the virus (the CD4 a agnostic and /or prognostic indi ch cases, CD8 lymphocyte level tform (SP) technology especially a ENERATED INHOUSE BY SINGLI 5/CD3/CD4/CD8) with Flow Cou **End Of Report vorld.com for related Tes	nus) derived and ine. The present ells via specific b sitive lymphocy ) results in prog ntigen). Clinical icators of immun Is might be norm chnology allows d at lower counts. E PLATFORM TEC unt Flurospheres t** st Informatic	B (bone marrow-d test utilizes mono- inding to cell surfa mune status, unde tess might also assi ressive immunosuj and immunologic c e competence. CD hal, increased or de lirect measuremen CHNOLOGY. for absolute count on for this acce	derived). These cell types clonal antibodies against ( icc antigens, CD3, CD4 ar rlying known or unknown st in the diagnosis and /o opression due predominar leterioration generally cor d/CDB ratio fails toward z creased. t of lymphocyte subsets to t determination. ession	are morphologically CD3, CD4 and CD8 to d CD8 respectively. disease states and to r monitoring of titly to a selective relates with a falling ero in advanced AIDS by Flow Cytometric
Test Method(s) LYMPHOCYTE SUBSET ENUMERATION, BLOOD- LYMPHOCYTE SUBSET ENUMERATION Introduction: The lymphocyte population of human peripheral blood is com indistinguishable but can be identified by characteristic antige identity and enumerate peripheral blood mature helper/induc Applications: CD3, CD4 and/or CDB positive lymphocyte percentages and a monitor lymphocyte levels following organ transplantation. D immunodeficiency diseases. For example, infection with hum- depletion of the CD4 positive lymphocytes that express the rr CD4 positive lymphocyte count. CD4/CD8 ratio is useful as di patients, with no detectable levels of CD4 lymphocytes. In su Technique: Assolute CD4 and CD8 counts are carried out using single pla analysis alone and is more accurate, compared to the "dual p GENDERWISE REFERENCE RANGES QUOTED ABOVE WERE G Methodology: Single Platform/Direct analysis using four-color reagent (CD4 Metage visit www.srlv Dr. Vishal Mehrotra, MD Haematopathologist	posed of two cell types: T (thym nic profile on their cell membra er and supresssor/cytoxic.F co termination of levels of CD4 pc an immunodeficiency virus (HIV ceptor for the virus (the CD4 a agnostic and /or prognostic Indi ch cases, CD8 lymphocyte level tform (SP) technology. This tec latform" technology especially a ENERATED INHOUSE BY SINGLI 5/CD3/CD4/CD8) with Flow Cot **End Of Report vorld.com for related Te:	nus) derived and ine. The present ells via specific b sitive lymphocy ) results in prog ntigen). Clinical icators of immun Is might be norm chnology allows d at lower counts. E PLATFORM TEC unt Flurospheres t** st Informatic	B (bone marrow-d test utilizes mono- inding to cell surfa mune status, unde tes might also assi ressive immunosuj and immunologic c e competence. CD hal, increased or de lirect measuremen CHNOLOGY. for absolute count on for this acce	derived). These cell types clonal antibodies against ( icc antigens, CD3, CD4 ar rlying known or unknown sin the diagnosis and /o opression due predominar leterioration generally cor d/CDB ratio fails toward z creased. t of lymphocyte subsets to t determination. ession	are morphologically CD3, CD4 and CD8 to d CD8 respectively. disease states and to r monitoring of tity to a selective relates with a falling ero in advanced AIDS by Flow Cytometric
Test Method(s) LYMPHOCYTE SUBSET ENUMERATION, BLOOD- LYMPHOCYTE SUBSET ENUMERATION Introduction: The lymphocyte population of human peripheral blood is com indistinguishable but can be identified by characteristic antigu didentity and enumerate peripheral blood mature helper/induc Applications: CD3, CD4 and/or CDB positive lymphocyte percentages and a monitor lymphocyte levels following organ transplantation. D immunodeficiency diseases. For example, infection with hum- depletion of the CD4 positive lymphocytes that express the rr CD4 positive lymphocyte count. CD4/CD8 ratio is useful as di patients, with no detectable levels of CD4 lymphocytes. In su Technique: Application: GENDERWISE REFERENCE RANGES QUOTED ABOVE WERE G Methodology: Single Platform/Direct analysis using four-color reagent (CD4 Methodology: Dr. Vishal Mehrotra, MD Haematopathologist	posed of two cell types: T (thym nic profile on their cell membra er and supressor/cytoxic.F co teermination of levels of CD4 pc an immunodeficiency virus (HIV ceptor for the virus (the CD4 a agnostic and /or prognostic indi ch cases, CD8 lymphocyte level tform (SP) technology. This tec latform" technology especially a ENERATED INHOUSE BY SINGLI 5/CD3/CD4/CD8) with Flow Cou **End Of Report vorld.com for related Te:	nus) derived and ine. The present ells via specific b sitive lymphocy ) results in prog ntigen). Clinical icators of immun Is might be norm chnology allows d at lower counts. E PLATFORM TEC unt Flurospheres t** st Informatic	B (bone marrow- test utilizes monoi inding to cell surfa mune status, unde tes might also assi ressive immunosuj and immunologic c e competence. CD al, increased or de lirect measuremen CHNOLOGY. for absolute count on for this acce	Jerved). These cell types clonal antibodies against of cea antigens, CD3, CD4 ar rlying known or unknown st in the diagnosis and /o ppression due predominar leterioration generally cor 4/CD8 ratio falls toward z creased. t of lymphocyte subsets t t determination. cssion	are morphologically CD3, CD4 and CD8 to d CD8 respectively. disease states and to r monitoring of titly to a selective relates with a falling rero in advanced AIDS by Flow Cytometric
Test Method(s) LYMPHOCYTE SUBSET ENUMERATION, BLOOD- LYMPHOCYTE SUBSET ENUMERATION Introduction: The lymphocyte population of human peripheral blood is com indistinguishable but can be identified by characteristic antigu didentity and enumerate peripheral blood mature helper/induc Applications: CD3, CD4 and/or CDB positive lymphocyte percentages and a monitor lymphocyte levels following organ transplantation. D immunodeficiency diseases. For example, infection with hum- depletion of the CD4 positive lymphocytes that express the rr CD4 positive lymphocyte count. CD4/CD8 ratio is useful as di patients, with no detectable levels of CD4 lymphocytes. In su Technique: Application: GENDERWISE REFERENCE RANGES QUOTED ABOVE WERE G Methodology: Single Platform/Direct analysis using four-color reagent (CD4 Methodology: Dr. Vishal Mehrotra, MD Haematopathologist	posed of two cell types: T (thym nic profile on their cell membra er and supressor/cytoxic.F co termination of levels of CD4 pc an immunodeficiency virus (HIV ceptor for the virus (the CD4 a agnostic and /or prognostic indi ch cases, CD8 lymphocyte level tform (SP) technology. This tec latform" technology especially a ENERATED INHOUSE BY SINGLI 5/CD3/CD4/CD8) with Flow Cou **End Of Report vorld.com for related Te:	nus) derived and ine. The present ells via specific b sitive lymphocy ) results in prog ntigen). Clinical icators of immun Is might be norm chnology allows d at lower counts. E PLATFORM TEC unt Flurospheres t** st Informatic	B (bone marrow- test utilizes monoi inding to cell surfa mune status, unde tes might also assi ressive immunosuj and immunologic c e competence. CD al, increased or de lirect measuremen CHNOLOGY. for absolute count on for this acce	Jerved). These cell types clonal antibodies against of cea antigens, CD3, CD4 ar rlying known or unknown st in the diagnosis and /o ppression due predominar leterioration generally cor 4/CD8 ratio falls toward z creased. t of lymphocyte subsets t t determination. cssion	are morphologically CD3, CD4 and CD8 to dd CD8 respectively. disease states and to r monitoring of tity to a selective relates with a falling ero in advanced AIDS by Flow Cytometric
Test Method(s) LYMPHOCYTE SUBSET ENUMERATION, BLOOD- LYMPHOCYTE SUBSET ENUMERATION Introduction: The lymphocyte population of human peripheral blood is com indistinguishable but can be identified by characteristic antige dientify and enumerate peripheral blood mature helper/induc Applications: CD3, CD4 and/or CDB positive lymphocyte percentages and a monitor lymphocyte levels following organ transplantation. D immunodeficiency diseases. For example, infection with hum- depletion of the CD4 positive lymphocytes that express the rr CD4 positive lymphocyte count. CD4/CD8 ratio is useful as di patients, with no detectable levels of CD4 lymphocytes. In su Technique: Absolute CD4 and CD8 counts are carried out using single pla analysis alone and is more accurate, compared to the "dual p GENDERWISE REFERENCE RANGES QUOTED ABOVE WERE G Methodology: Single Platform/Direct analysis using four-color reagent (CD4 Please visit www.srlv Dr. Vishal Mehrotra, MD Haematopathologist	posed of two cell types: T (thym nic profile on their cell membra er and supressor/cytoxic.F co termination of levels of CD4 pc an immunodeficiency virus (HIV ceptor for the virus (the CD4 a agnostic and /or prognostic indi ch cases, CD8 lymphocyte level tform (SP) technology. This tec latform" technology especially a ENERATED INHOUSE BY SINGLI 5/CD3/CD4/CD8) with Flow Cou **End Of Report vorld.com for related Te:	nus) derived and ine. The present ells via specific b sitive lymphocy ) results in prog ntigen). Clinical icators of immun Is might be norm chnology allows of at lower counts. E PLATFORM TEC unt Flurospheres t** st Informatic	B (bone marrow- test utilizes monoi inding to cell surfa mune status, unde tes might also assi ressive immunosuj and immunologic c e competence. CD al, increased or de lirect measuremen CHNOLOGY. for absolute count on for this acce	derived). These cell types clonal antibodies against of ce antigens, CD3, CD4 ar rlying known or unknown st in the diagnosis and /o ppression due predominar leterioration generally cor 4/CD8 ratio falls toward z ccreased. t of lymphocyte subsets t t determination. cssion	are morphologically CD3, CD4 and CD8 to dd CD8 respectively. disease states and to r monitoring of tity to a selective relates with a falling ero in advanced AIDS by Flow Cytometric
Test Method(s) LYMPHOCYTE SUBSET ENUMERATION, BLOOD- LYMPHOCYTE SUBSET ENUMERATION Introduction: The lymphocyte population of human peripheral blood is com indistinguishable but can be identified by characteristic antige dientity and enumerate peripheral blood mature helper/induc Applications: CD3, CD4 and/or CDB positive lymphocyte percentages and a monitor lymphocyte levels following organ transplantation. D immunodeficiency diseases. For example, infection with hum- depletion of the CD4 positive lymphocyte strate express the rr CD4 positive lymphocyte count. CD4/CD8 ratio is useful as di patients, with no detectable levels of CD4 lymphocytes. In su Technique: Absolute CD4 and CD8 counts are carried out using single pla analysis alone and is more accurate, compared to the "dual p GENDERWISE REFERENCE RANGES QUOTED ABOVE WERE G Methodology: Single Platform/Direct analysis using four-color reagent (CD4 Please visit www.srlv Dr. Vishal Mehrotra, MD Haematopathologist	posed of two cell types: T (thym nic profile on their cell membra er and supressor/cytoxic.F co termination of levels of CD4 pc an immunodeficiency virus (HIV ceptor for the virus (the CD4 a agnostic and /or prognostic indi ch cases, CD8 lymphocyte level tform (SP) technology. This tec latform" technology especially a ENERATED INHOUSE BY SINGLI 5/CD3/CD4/CD8) with Flow Cou **End Of Report vorld.com for related Te:	nus) derived and ine. The present ells via specific b sitive lymphocy ) results in prog ntigen). Clinical icators of immun Is might be norm chnology allows of at lower counts. E PLATFORM TEC unt Flurospheres t** st Informatic	B (bone marrow- test utilizes monoi inding to cell surfa mune status, unde tes might also assi ressive immunosuj and immunologic c e competence. CD al, increased or de lirect measuremen CHNOLOGY. for absolute count on for this acce	derived). These cell types clonal antibodies against of ce antigens, CD3, CD4 ar rlying known or unknown st in the diagnosis and /o ppression due predominar leterioration generally cor 4/CD8 ratio falls toward z ccreased. t of lymphocyte subsets t t determination. cssion	are morphologically CD3, CD4 and CD8 to dd CD8 respectively. disease states and to r monitoring of tity to a selective relates with a falling ero in advanced AIDS by Flow Cytometric
Test Method(s) LYMPHOCYTE SUBSET ENUMERATION, BLOOD- LYMPHOCYTE SUBSET ENUMERATION Introduction: The lymphocyte population of human peripheral blood is com indistinguishable but can be identified by characteristic antige dientity and enumerate peripheral blood mature helper/induc Applications: CD3, CD4 and/or CDB positive lymphocyte percentages and a monitor lymphocyte levels following organ transplantation. D immunodeficiency diseases. For example, infection with hum- depletion of the CD4 positive lymphocytes that express the rr CD4 positive lymphocyte count. CD4/CD8 ratio is useful as di patients, with no detectable levels of CD4 lymphocytes. In su Technique: Absolute CD4 and CD8 counts are carried out using single pla analysis alone and is more accurate, compared to the "dual p GENDERWISE REFERENCE RANGES QUOTED ABOVE WERE G Methodology: Single Platform/Direct analysis using four-color reagent (CD4 Please visit www.srlv Dr. Vishal Mehrotra, MD Haematopathologist	posed of two cell types: T (thym nic profile on their cell membra er and supressor/cytoxic.F co tetermination of levels of CD4 pc an immunodeficiency virus (HIV ceptor for the virus (the CD4 a agnostic and /or prognostic indi ch cases, CD8 lymphocyte level tform (SP) technology. This tec latform" technology especially a ENERATED INHOUSE BY SINGLI 5/CD3/CD4/CD8) with Flow Cou **End Of Report vorld.com for related Tes	nus) derived and ine. The present ells via specific b sitive lymphocy ) results in prog ntigen). Clinical icators of immun Is might be norm chnology allows d at lower counts. E PLATFORM TEC unt Flurospheres t** st Informatic	B (bone marrow- test utilizes monoi inding to cell surfa mune status, unde tes might also assi ressive immunosuj e competence. CD al, increased or de lirect measuremen CHNOLOGY. for absolute count on for this acce	derived). These cell types clonal antibodies against of ce antigens, CD3, CD4 ar rlying known or unknown st in the diagnosis and /o ppression due predominar leterioration generally cor 4/CD8 ratio falls toward z ccreased. t of lymphocyte subsets t t determination. ession	are morphologically CD3, CD4 and CD8 to did CD8 respectively. disease states and to r monitoring of thy to a selective relates with a falling ero in advanced AIDS by Flow Cytometric

N



Age & Sex: 40, Male

Ref. No: Sudharma Shoranur

: Jul 04, 2015

Date

ENTROLOGICE CERTIFIC

Ref. By : Dr.

No.	INVESTIGATION	PATIENT'S VALUE	NORMAL RANGE
1	Blood Sugar (F)	99 mg/dl	70 - 110 mg/dl
2	Urea	24.6 mg/dl	15 - 45 mg/dl
3	Creatinine	/ 1.16 mg/dl	0.60 - 1.40 mg/dl
4	Uric Acid	4.2 mg/dl	M : 3.40 - 7.00 F : 2.00 - 6.00 mg/dl
5	Calcium	9.6 mg/dl	8.5 - 10.5 mg/dl
6	Phosphorous	4.1 mg/dl	2.5 - 4.8 mg/dl
7	Sodium	142 mEq/L	135 - 145 mEq/L
8	Pottassium	4.4 mEq/L	3.8 - 5.0 mEq/L
9	Chloride	100 mEq/L	98 -106 mEq/L
10	Bicarbonate	21 mEq/L	20 -28 mEq/L
11	Blood Sugar (PP)	116 mg/dl	80 - 140 mg/dl

Remarks:





		1	
NO.	INVESTIGATION	PATIENT'S VALUE	NORMAL RANGE
1	Bilirubin Total	0.88 mg/dl	Upto 1.2 mg/dl
2	Bilirubin Direct	0.14mg/dl	0.0 - 0.3 mg/dl
3	SGOT (AST)	52 U/L	5 - 35 U/L
4	SGPT(ALT)	60 U/L	5 - 40 U/L
5	Alkaline Phosphatase	214 U/L	100 - 250 U/L
6	Total Protein	7.40 gm/dl	6.3 - 8.2 gm/dl
7	Albumin	4.10 gm/dl	3.5 - 5.0 gm/dl
8	Globulin	3.30 gm/dl	2.3 - 3.5 gm/dl
9	A/G Ratio	1.24	
	1		

## LIVER FUNCTION TEST

Remarks:

Jul 04, 2015, 2:22:25 PM Mr. Irshad Ahamed DMLT. Working hours : 6.30 AM-7.30 PM Sunday : 6.30 AM-12 Noon Malabar Shopping Mall Male Pattambi Tel : 0466-2211559, 3203920 Vear Bus Stand<br/>Aain Road,MannarkkadNear Bus Stand<br/>Bye Pass Road ,KondottyNear Juma Masjid<br/>Changuvetty,Kottakkal<br/>Ph : 04924 201 201Ph : 04924 201 201Ph : 0483-2711113Ph : 0483-2741211 Opp. Govt. Hospital Cherupulassery Ph : 0466 - 2207806 SRS Building Karadi, Thamarassery Ph: 0495 2223727



# HAEMOGRAM INTERPRETATION

# PATIENT'S VALUE

		and president and a state of the		
	ABSOLUTE VALUE	NORMAL RANGE	% VALUE	NORMAL RANGE
WBC	6,600/cu mm.	5,000 - 12,000 /cu mm		
NEU (Neutrophil)	3,690/cu mm/.	1,700 - 7,800 /cu mm.	56 % N	35.0 - 65.0 % N
LYM (Lymphocyte)	2,640/cu mm.	1,250 - 5,400 /cu mm.	40 % L	25.0 - 45.0 % L
MONO (Monocyte)	70/cu mm.	0 - 600 /cu mm.	01 % M	0.0 - 6.0 % M
EOS (Eosinophil)	200/cu mm.	0 - 600 /cu mm.	03 % E	0.0-6.0 % E
BASO (Basophil)	0/cu mm.	0.00100 /cu mm.	00 % B	0.0 - 2.0 % B
RBC	5.0 M/ul	4.50 - 6.50 M/uL		
HGB (Hb)	13.6 g/dl	12.0 - 15.0 g/d L		
HCT (Hematocrit) - PCV	41.8%	33.0 - 45.0 %		
MCV	83.60 fL	82.0 - 92.0 fL		n an
МСН	27.20 р g	27.0 - 32.0 pg		Search of the state of the stat
МСНС	32.54 g / dL	32.0 - 36.0 g/dL		
PLT (Platelets)	186,000 /cu mm.	100000 - 350000 /cu mm.		
ESR	36mm / hr.	Upto 20 mm / hr.		

Remarks:

Jul 04, 2015, 2:22:25 PM

Mr. Irshad Ahamed DMLT.

Working hours i Gian AM-7.30 PM Sunday : 6.30 AM-12 Noon

Malabar Shopping Mall Male Pattambi Tel: 0466-2211559, 3203920

Branches

Near Bus Stand<br/>Main Road, Mannarkkad<br/>Ph : 04924 201 201Near Bus Stand<br/>Bye Pass Road, Kondotty<br/>Ph : 0483-2711113Near Juma Masjid<br/>Changuvetty, Kottakkal<br/>Ph : 0483-2741211SRS Building<br/>Karadi, Thamarassery<br/>Ph : 0495 2223727

Opp. Govt. Hospital Cherupulassery Ph: 0466 - 2207806





Colour	Pale Yellow	MICI	ROSCOPY
Reaction	Acidic	Red Blood Cells	Nil
Specific Gravity	-	Pus Cells	1 - 2/ hpf
Albumin	Faint Trace	Epithelial Cells	+
Sugar	Nil	Cast	Nil
Acetone	-	Crystals	Nil
Bile pigments	Nil	Bacteria	
Bile salt	Negative	Ammor. Urates	
Urobilinogen	-		
Porphobilinogen	-		

# URINE ANALYSIS

Remarks:

Jul 04, 2015 2:22:25 PM

Mr. Irshad Ahamed DMIT. Chief Technician

Working hours : 6.30 AM-7.30 PM Sunday : 6.30 AM-12 Noon

Aalabar Shopping Mall Ale Pattambi el : 0466-2211559, 3203920

Vear Bus Stand Aain Road, MannarkkadBye Pass Road, Kondottyh : 04924 201 201Ph : 0483-2711113

Near Bus Stand

Near Juma Masjid Changuvetty,Kottakkal Ph: 0483-2741211

SRS Building Karadi, Thamarassery Ph: 0495 2223727

Opp. Govt. Hospital Cherupulassery Ph: 0466 - 2207806





NO.	INVESTIGATION	PATIENT'S VALUE	NORMAL RANGE	
1	Cholesterol	<b>172.00</b> mg/dl	Desirable:< 200 mg/	d1 d1 d1
2	Triglycerides	<b>180.00</b> mg/dl	Desirable         :         < 150 mg/           Borderline High         :         150 - 199 mg/           High         :         > 200 mg/	d1 d1 d1
3	HDL Cholesterol	<b>44.0</b> mg/dl	Desirable:> 40 mg/Borderline High:35 - 39 mg/Undesirable:< 35 mg/	dl dl dl
. 4	LDL Cholesterol	<b>107.00</b> mg/dl	Optimal         :         < 100 mg/           Near / Above Opitimal         :         100 - 129 mg/           Borderline High         :         130 - 159 mg/           High         :         >	d1 d1 d1 d1
5	VLDL Cholesterol	<b>36.00</b> mg/dl	14 - 42 mg/dl	
6	Cholesterol / HDL Cholesterol Ratio	3.9:1	Up To 5.0	

# LIPID PROFILE REPORT

Chief Technician

Working hours 6.30 AM-7.30 PM Sunday : 6.30 AM-12 Noon



SPECIALTY LABORATOR P.K Tower, Opp. Juma Mas Main Road, SHORANUR-1 Ph : 0466 -2222258 Mob : 75 59 91 22 58	A RY sjid I	AIAQ-BAR INCOMENTATION AIAQ-BAR A
Name : Mr.	Age & Sex: 40, Male	Ref. No:
		Sudharma Shoranur
Ref. By :Dr.		Date : Jul 04, 2015

No.	INVESTIGATION	RESULT
1	HIV - 1&2 - (Tri-Dot)	Negative
2	HBsAg - (Card Test)	Negative
3	VDRL/RPR	Non Reactive
1		





No.	INVESTIGATION	PATIENT'S VALUE	NORMAL RANGE
1	RA Factor - Quantitative (by Nephelometry)	13.0 IU/ml	< 35 IU/ml
2	ASO Titre - Quantitative (by Nephelometry)	65 IU/ml	< 200 IU/ml

lemarks:

£₽	are	-	а. н., с <sup>1</sup>	Jul 04, 2	2015,2:28:51	PM
Mr. Irshad Al	named DMILT.					
Working Poweria	0 AM-7.30 PM Sunday : 6	.30 AM-12 Noon				
alabar Shopping Mall ale Pattambi II : 0466-2211559, 3203	3920					UDHARMA
ear Bus Stand ain Road,Mannarkkad 1 : 04924 201 <mark>2</mark> 01	Near Bus Stand Bye Pass Road ,Kondotty Ph : 0483-2711113	Near Juma Masjid Changuvetty,Kottakkal Ph : 0483-2741211	SRS Building Karadi,Thamarassery Ph : 0495 2223727	Opp. Govt. Hospital Cherupulassery Ph : 0466 - 2207806		

				World's largest thyroid testing lab	orato
Thyrocare				ACCREDITED   NETWORKED   BAR	RCODI
1078, Senthil towers,	OPI C123882) Thyrocar	P. D-37/3 TTC	MIDC Turb	he. Navi Mumbai - 400703.	
Coimbatore ph.: 022 - 3090 0000 / 4125 2525   Fa	ax: 2768 2409   Email: i	nfo@thyrocare	e.com   Web	site: www.thyrocare.com	1
	REPOR	T	AND STORES		19196
		SAMP		TED AT :	
		(6111)	, CARE LABOR	TORY OPPOSITE TO SEMALK	
TEST ASKED : TSH		OTTAPALAM ,PALAKKAD DISTRICT.		D DISTRICT.	
TEST NAME	TECHNOLOGY	VALUE	UNITS	REFERENCE RANGE	
THYROID STIMULATING HORMONE (TSH)	C.L.I.A	2.35	µIU/ml	0.30 - 5.5	
Comments: ***			A di mane		

~~ End of report ~~



Sample Collected on (SCT) Sample Received on (SRT) Report Released on (RRT) Sample Type Labcode Barcode : 03 Jul 2015 08:00 : 04 Jul 2015 00:22 : 04 Jul 2015 02:50 : SERUM : 030726392/KER05 : 52022320

Dr.Alap Christy MD

Gu.

Dr.Caesar Sengupta MD Page : 1 of 1

Reporting conditions overleaf

## DISCUSSION

All patients had gained boosted immune T-cells and the lymphocyte common antigen CD45+ count was highly increased at about >40 %.

5 Kg body weight was increased. Fourthgeneration tests look for both antibodies and antigens.

Antigens are proteins on the surface of the HIV particle. Antibodies are produced by the immune system in response to the HIV antigens.

They fit together like a lock and key. The p24 tests, fourth generation tests, as Tri-Dot and Duo tests were carried out.

# REFERENCES

No references were matched in this study. Author approves this final Manuscript.

# CONCLUSION

No seronegative illness was found. The patient's immune T-cells were highly boosted and they (2 patients) strongly HIV negative. This beneficial study is aiming to recruit 1000 HIV+ patients all over India. More outstanding phase- III observation study is needed. Lack of funding from any source is a big concern to initiate viral load assay and it was not carried out in this study.

## ACKNOWLEDGEMENT

U.S. NIH trained Scientist. No personal conflict of interest. Anticipate possible funding from the National Institute of Allergy and Infectious Diseases NIAID